Check Out the Latest Buzz on FastWave

This latest patent covers FastWave's laser IVL technology, which is specifically being developed to tackle calcified arteries.

As featured in Los Angeles Times, FastWave is advancing the future of IVL.

As covered by Medical Alley, clinical-stage medical device company receives new patent for advanced laser intravascular lithotripsy (IVL) technology designed to address the global challenge of calcified arteries.

This patent covers FastWave's groundbreaking laser IVL technology, specifically engineered to address calcified arteries — a condition affecting millions worldwide and a major challenge in cardiovascular care.

As featured in the WSJ Pro Venture Capital newsletter, Minneapolis-based FastWave added $19 million in funding led by Epic Venture Partners.

Fastwave's IVL catheter is being developed as a competitor to Shockwave with and an increased number of lithotripsy pulses and faster deliver.

As featured in Cardiac Invterventions Today, the funds will fuel FastWave’s development momentum and provide support for ongoing regulatory and clinical initiatives for its portfolio of IVL platforms to treat artery calcification.

FastWave Medical announced the close of a $19 million funding round, increasing the total capital invested into the company to over $40 million.

This investment round was led by Epic Venture Partners with participation from M&L Healthcare Investments and the company’s existing investors.

This recent funding round increases the total capital invested into FastWave to over US$40 million.

After securing an additional $19 million in funding led by Epic Venture Partners, FastWave Medical is set to advance its pipeline of next-generation IVL platforms.

As featured in MassDevice, FastWave announced that it closed an oversubscribed funding round worth proceeds of $19 million.

FastWave Medical has announced the issuance of its sixth utility patent by the USPTO, the fourth patent the company has been granted this year.

As covered by Medical Alley, clinical-stage medical device company further strengthens its intellectual property position with a new patent from the USPTO for FastWave’s advanced intravascular lithotripsy (IVL) technology.

As featured in Vascular News, FastWave Medical has announced the issuance of its sixth utility patent. This is the fourth patent the company has been granted this year.

As covered in Interventional News, FastWave has announced the issuance of its sixth utility patent by the USPTO.

As featured in MassDevice, FastWave announced the sixth patent for its intravascular lithotripsy (IVL) technology for treating calcific artery disease.

FastWave Medical, a developer in advanced intravascular lithotripsy (IVL) technology, announced the issuance of its sixth utility patent by the USPTO.

Dr. Amir Kaki shares insights from seasoned cardiologists and vascular surgeons based on FastWave fellows-themed interviews.

Based on a few FastWave fellows-themed interviews, Dr. Art Lee brings together insights from seasoned cardiologists and vascular surgeons.

Early glimpses of next-generation advancements by FastWave Medical promise to advance IVL technology so that even more patients can benefit from this breakthrough technology.

As featured in Vascular News, FastWave has announced the 30-day results of its FIH study using its differentiated peripheral IVL technology.

FastWave has announced the 30-day results of its first-in-human study using the company’s differentiated peripheral intravascular lithotripsy technology.

As covered in Interventional News, FastWave's prospective, single-arm study assess the safety and feasibility of the its IVL system in patients with peripheral arterial disease affecting the superficial femoral artery (SFA) and popliteal artery with moderate to severe calcium.

As covered by Endovascular Today, FastWave Medical announced the 30-day results of its first-in-human (FIH) study using the company’s peripheral intravascular lithotripsy (IVL) technology.

FastWave’s peripheral IVL platform showcases promising 30-day results in the first-in-human study demonstrating safety and feasibility in patients with moderate to severe calcified obstructive disease in the superficial femoral and popliteal arteries.

As featured in MassDevice, study evidence supported early safety and feasibility of FastWave's peripheral IVL system.

As covered in Cath Lab Digest, this study demonstrates FastWave IVL technology's safety and feasibility in patients with moderate to severe calcific disease in the superficial femoral and popliteal arteries.

As featured in MassDevice, FastWave Medical announced that the USPTO issued it another intravascular lithotripsy (IVL) utility patent.

As featured in Vascular News, FastWave has been issued its fifth utility patent by the USPTO.

FastWave Medical, which is developing advanced intravascular lithotripsy (IVL) technology, achieves a significant milestone with the issuance of its fifth utility patent by the USPTO.

As covered in Cath Lab Digest, FastWave announced the issuance of its fifth utility patent by the USPTO.

As covered by Endovascular Today, A panel interview with Drs. Arthur Lee, Amir Kaki, Miguel Montero-Baker, Venkatesh Ramaiah, and Peter Schneider, on advances in treating calcific PAD with IVL.

As covered by Endovascular Today, FastWave Medical announced further developments for its preclinical intravascular lithotripsy (IVL) technology that aims to address challenges associated with treating calcified arteries in patients with occlusive vascular disease.

FastWave Medical has announced the issuance of its fourth utility patent by the USPTO for its laser-intravascular lithotripsy (IVL) platform.

As covered in Cath Lab Digest, FastWave announced the issuance of its fourth utility patent by the USPTO.

As featured in MassDevice, FastWave Medical announced that it received a fourth utility patent to strengthen the IP foundation of its IVL platform.

VentureBeat highlights the rapid progress that the FastWave team has made since we started the company in 2021.

In this feature, Barnaby Pickering of Citeline speaks to Scott Nelson, CEO of FastWave Medical, about the advancements the startup is making in the intravascular lithotripsy (IVL) space.

As covered by Cardiovascular News, FastWave Medical has announced the issuance of its third utility patent by the US Patent and Trademark Office.

The company's newly granted patent supports the differentiated design of FastWave’s next-generation IVL system, which aims to address challenges associated with treating calcified arteries in patients with occlusive vascular disease.

As covered in Cath Lab Digest, FastWave Medical continues to push the boundaries of calcific artery disease treatment with latest patent from USPTO.

As featured in Vascular News, FastWave Medical has announced the issuance of its third utility patent by the US Patent and Trademark Office.

As featured in Cardiac Invterventions Today, FastWave Medical announced the issuance of its third utility patent by the US Patent and Trademark Office that supports the differentiated design of FastWave’s next-generation IVL system. It also recently appointed a new medical advisors board.

As covered by Endovascular Today, FastWave Medical, a device company focused the treatment of calcified cardiovascular disease through intravascular lithotripsy (IVL), recently announced the appointments of eight medical advisors. Additionally, the company announced the issuance of its third utility patent by the US Patent and Trademark Office.

In this episode of Device Talks, host Tom Salemi talks with FastWave CEO, Scott Nelson, about strategies for breaking into medtech markets.

As featured in Vascular News, FastWave Medical has announced the successful completion of enrolment for its first-in-human (FIH) study with the company’s peripheral intravascular lithotripsy (IVL) technology.

As covered by Endovascular Today, FastWave Medical announced the completion of enrollment for the first-in-human (FIH) study of its peripheral intravascular lithotripsy (IVL) technology.

Scott Nelson, CEO of FastWave Medical, elaborates why the most important ingredient in having a successful medtech startup revolves around networking. Learn more in this op-ed featured in MD+DI.

As covered in Cath Lab Digest, FastWave Medical completes enrollment for the first-in-human study of its innovative peripheral intravascular lithotripsy system, marking a significant milestone for the fast-moving company.

As featured in MassDevice, FastWave Medical announced the successful completion of enrollment for its first-in-human study of its peripheral intravascular lithotripsy (IVL) system to treat calcified cardiovascular disease.

In this op-ed for Forbes, FastWave's CEO Scott Nelson talks about early implementation of effective risk management for medtech startups.

FastWave Medical announced the successful completion of enrollment for its first-in-human study of its peripheral intravascular lithotripsy (IVL) system to treat calcified cardiovascular disease.

In this op-ed published on MD+DI, FastWave CEO, Scott Nelson talks about strategies that can help a medtech startup reach success.

FastWave CEO Scott Nelson was featured in MD+DI’s ‘24 Medtech Voices to Follow in 2024’.

In this op-ed for Forbes, FastWave's CEO Scott Nelson elaborates on 5 tips to ensure product-market fit in medtech.

In this op-ed for Forbes, FastWave's CEO Scott Nelson outlines how to position medtech startups for succesful exits.

Five experts reveal what it takes to make it in the medtech industry. Learn more in this op-ed featured in MD+DI.

As featured in MD+DI, FastWave Medical closes oversubscribed private financing round to develop its IVL systems.

As featured in Cardiac Invterventions Today, FastWave Medical announced the closure of an oversubscribed multimillion dollar private financing. The capital will support the continued development of FastWave’s intravascular lithotripsy (IVL) systems for calcific artery disease, propelling the company’s key preclinical and clinical initiatives.

As featured in MassDevice, FastWave Medical announced that it closed an oversubscribed, multi-million-dollar private financing round. The Minneapolis-based medical device company says the financing — secured in just a few weeks — highlights the growing interest in its intravascular lithotripsy (IVL) offerings.

As covered in Cath Lab Digest, significant interest in FastWave Medical leads to the rapid close of a private financing, with notable physician key opinion leaders (KOLs) and medical device industry stakeholders among the investors.

In this op-ed for Forbes, FastWave's CEO Scott Nelson shares five key strategies that drive success for medical device startups.

Three entrepreneurs, including FastWave's COO Tristan Tieso, share tips on how to develop groundbreaking devices in the medtech industry. Learn more in this op-ed featured in MD+DI.

Device developer FastWave Medical is working to advance intravascular lithotripsy therapy for peripheral and coronary artery disease. Learn more in this op-ed written by FastWave's COO, Tristan Tieso, which is featured in Medical Design & Outsourcing.

Arterial calcium can be dealt with using atherectomy tools to grind away debris from the inside of the vessel, but it is more challenging to remove from the medial layer of vessel tissue. Intravascular lithotripsy (IVL) addresses this discrepancy with an energy-based solution, and FastWave Medical is developing multiple IVL platforms that build upon currently available technology. Read more in this piece from Medtech Strategist.

Entrepreneurs who are willing to leverage proven DTC strategies can gain a competitive advantage in medtech, argues Scott Nelson, co-founder and CEO of FastWave Medical. Read more in this op-ed piece published in MedTech Dive.

In this interview with host Giovanni Lauricella and his guest Scott Nelson, they discuss the best and worst piece of advise Scott’s received about raising money, why a no isn’t alway a no from an investor, raising money from a Chinese strategic, and so much more.

FastWave's second utility patent from the USPTO in just over a year highlights the rapid progress its team has made in advancing IVL treatments for cardiovascular calcium. Read more coverage from Diagnostic and Interventional Cardiology.

FastWave Medical announced it has been awarded a utility patent from the USPTO for its novel intravascular lithotripsy (IVL) solution for peripheral and coronary artery calcification (CAC). Read more coverage from Medical Alley.

FastWave Medical announced the closing of the second tranche of its Series Pre-A financing. The funds will be used to further advance research and development for the company’s intravascular lithotripsy (IVL) systems and help the company achieve key regulatory initiatives for its technology platforms. Read more coverage from Endovascular Today.

Proceeds from the second tranche of funding will be used to further advance research and development for FastWave’s proprietary intravascular lithotripsy (IVL) systems for the treatment of calcific artery disease. The investment will also help the company achieve key regulatory initiatives for its technology platforms. Read more coverage from Medical Alley.

The latest phase of financing demonstrates the continued confidence from the company's investor in FastWave’s ability to execute against its development milestones. New financing will further support the development of FastWave’s proprietary intravascular lithotripsy systems. Read more coverage from Cath Lab Digest.

FastWave Medical Inc., a company incubated by partners of Big Sky Biomedical, announced today the closing of its Series Pre-A financing, led by a strategic partner from Asia. FastWave Medical is focused on providing endovascular solutions for arterial disease. Read more coverage from Endovascular Today.

Minority investment will be used to accelerate development and global expansion of the company’s novel endovascular therapies for arterial disease, and includes acquisition obligations upon the completion of key technical, clinical, and regulatory milestones. Read more coverage from Cath Lab Digest.

FastWave Medical Inc., a company incubated by partners of Big Sky Biomedical, announced today the closing of its Series Pre-A financing, led by a strategic partner from Asia. Read more coverage from Medical Alley.

FastWave Medical this week announced that it has closed its Series Pre-A financing round following its recent acquisition by China Grand Pharmaceutical and Healthcare Holdings. Read more coverage from MassDevice.